A worldwide leader in neuro-scientific radiosurgery.

Clinical study results of prostate cancer individuals treated with CyberKnife Radiosurgery released Accuray Incorporated , a worldwide leader in neuro-scientific radiosurgery, announced today publication of results from a scholarly research of early stage prostate cancer patients treated with CyberKnife Radiosurgery. The study demonstrated that erectile function was preserved in 81 % of individuals at a median follow-up of 2 yrs maximumdose . Published prices of erectile function preservation at two years for other typically used prostate cancer remedies, such as open surgery and regular radiation therapy, range between 50-70 %. This study of 112 patients, led by a united group of two radiation oncologists, a urologist and a physicist, attained 97 % sustained PSA response at two years, with rectal and urinary side effect profiles comparable to conventional radiation therapy.


. In a statement before the conference, Dr Brezina explained: In the IVF laboratory, all embryos that go through PGS on day three are cultured to the blastocyst stage of advancement at day five, of which period the PGS results are obtainable. In this study we evaluated all embryos that created to the blastocyst stage with documented chromosomal abnormalities not appropriate for a live birth from a cell extracted from the embryo on day time three. At the blastocyst stage, the embryo is rolling out into two parts; the inner cell mass , which has cells that may form the foetus, and the trophectoderm , which includes cells that will form the placenta.